Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded on the mission to discover, develop and commercialize innovative, first-in-class medicines that address significant unmet medical needs, today announced the appointment of Sue Hohenleitner as Chief Financial Officer (CFO), effective November 4, 2025. Ms. Hohenleitner is a proven financial leader, with more than 30 years of experience in corporate finance, strategic planning, investor relations and operations in a variety of therapeutic areas and stages of development. She has a proven track record of driving organizational transformation, building financial strength and driving sustainable growth across commercial and development-stage products. Ms. Hohenleitner most recently served as Vice President and Chief Financial Officer of Johnson & Johnson (J&J) Innovative Medicine North America (NA), where she led financial strategies for a $36 billion commercial company.
“I am pleased to welcome Sue to the Ardelyx leadership team,” said Mike Raab, president and CEO of Ardelyx. “Sue is an experienced and visionary financial leader whose proven ability to execute growth strategies and drive operational excellence makes her an exceptional addition to our company. Her forward-thinking approach, strategic insight and deep knowledge of our industry will be instrumental as we expand our commercial success and pursue new growth opportunities. Sue’s leadership and financial discipline will drive the momentum of Helping Ardelyx accelerate, strengthen our foundation and position the company for long-term success, enabling us to deliver meaningful value. for patients, employees and shareholders.”
“I am very excited to join Ardelyx at this important time in its evolution,” said Ms. Hohenleitner. “With two first-in-class medicines helping patients and plans for expansion in the coming years, I look forward to working with the team to determine strategic paths for long-term growth and innovation for patients everywhere, to develop the next generation of important medicines and to help patients who need our medicines most.”
Before joining Ardelyx, Ms. Hohenleitner enjoyed a 28-year career at J&J, where she led multiple financial organizations in areas including supply chain, innovation, commercial affairs, business development, investor relations, acquisitions and divestitures, and financial planning and analysis. As VP and CFO of J&J Innovative Medicine NA, Ms. Hohenleitner led a number of strategic initiatives that resulted in greater efficiency, effectiveness and financing for growth. Ms. Hohenleitner was also a critical partner during the acquisition of two key deals that resulted in successful commercial launches.
Ms. Hohenleitner is a Certified Public Accountant in the Commonwealth of Pennsylvania and a Certified Management Accountant. She earned a Bachelor of Science in Accounting from La Salle University and a Master of Business Administration from Villanova University. Ms. Hohenleitner was named a Top 25 CFO in Biotech by Entrepreneurship and investing.
Ms. Hohenleitner will assume the role of CFO on November 4, 2025, following the completion of Ardelyx’s third quarter 2025 financial reporting. Justin Renz, currently Chief Financial and Operations Officer, will continue in his role by filing Ardelyx’s Quarterly Report on Form 10-Q.
About Ardelyx
Ardelyx was founded with the mission to discover, develop and commercialize innovative, first-in-class medicines that address significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA ® (tenapanor) and XPHOZAH ® (tenapanor). Ardelyx has agreements to develop and commercialize tenapanor outside the US. Kyowa Kirin commercializes PHOZEVEL ® (tenapanor) for hyperphosphatemia in Japan. A new drug application for tenapanor for hyperphosphatemia has been approved in China by Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. For more information please visit https://ardelyx.com/ and contact us X (formerly known as Twitter) , LinkedIn And Facebook .
Investor and media contact
Caitlin Lowie
clowie@ardelyx.com
#Ardelyx #appoints #experienced #financial #director #Sue #Hohenleitner #Chief #Financial #Officer